Those who develop lupus as youngsters have more severe symptoms and a higher chance of an earlier death, according to a new study. The study in the British journal Lupus suggests that since patients with juvenile-onset systemic lupus erythematosus (JSLE) constitute a high-risk group, doctors need to devote extra attention…
The American Autoimmune Related Diseases Association (AARDA) recently announced its latest #AutoimmuneHeroes — its 22 Scientific Advisory Board (SAB) members who, over the past 25 years, have contributed their time and talents to advancing the association and helping it realize its goals of promoting research into lupus and other autoimmune…
A research study has shown the efficacy and safety of the Benlysta (belimumab), used in combination with other standard of care lupus treatments, such as antimalarials (AM), immunosuppressants (IS) and steroids. The findings may contribute to a better understanding of how Benlysta works as an add-on therapy for systemic lupus erythematosus (SLE). The…
The Lupus Research Alliance, newly formed from the merger of three different lupus groups, had its debut at the recent Inaugural Gala in New York, a fundraising event that collected over $2.5 million to support lupus research initiatives. The gala was co-hosted by Robert Wood Johnson IV, Lupus Research Alliance chairman and chief executive…
Aurinia Pharmaceuticals’ voclosporin showed considerable success in a clinical trial of lupus nephritis, according to recent data released by the company. Results found that the drug met the study’s primary goal of complete remission, and met all secondary goals of the ongoing, Phase 2b AURA-LV trial (NCT02141672). The data were…
An unprecedented $3 million was raised to support lupus research through two fundraising efforts, the 2016 Walk with Us to Cure Lupus program and the TCS NYC Marathon team, the Lupus Research Alliance announced. In total, the national Walk program has raised about $33.5 million since its 2002 inception, the Lupus Research Alliance said in a press…
Prolonged treatment with Benlysta (belimumab) offers safe and effective control of disease activity, improves life quality and eases fatigue in patients with active, autoantibody-positive systemic lupus erythematosus (SLE), according to seven-year clinical trial results released by GSK, the drug’s developer. These findings come from a continuation study of patients who completed the Phase…
Mallinckrodt Pharmaceuticals announced the enrollment of the first patients in the company’s Phase 4 clinical trial of H.P. Acthar Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus (SLE) patients with persistently active disease. The randomized and double-blind study (NCT02953821) will assess the effectiveness of the gel against…
Bilingual groups providing support and education to systemic lupus erythematosus (SLE) patients and their family members  — people who live in minority U.S. neighborhoods — considerably help them to manage and cope with the disease, a survey shows. The findings were recently presented at the recent American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) annual…
GlaxoSmithKline (GSK) reported positive data from a trial of Benlysta (belimumab) for systemic lupus erythematosus in Northeast Asia that will form the basis of a request for the treatment’s regulatory approval in Japan and China. Study findings (NCT01345253) were presented at the recent 2016 American College of Rheumatology/Association for Rheumatology…